x

Posted 22 March, 2023

Pacira BioSciences, Inc. appointed new CEO

CEO Change detected for ticker Nasdaq:PCRX in a 8-K filed on 22 March, 2023.


  On March 18, 2023, Yvonne Greenstreet notified the Board of Directors (the "Board") of Pacira BioSciences, Inc. (the "Company") of her intent to of her intent to retire from the Board, effective March 31, 2023. Dr. Greenstreet is currently serving as Chief Executive Officer of Alnylam Pharmaceuticals, Inc., a Nasdaq-listed public company.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Pacira BioSciences, Inc.
Health Care/Life Sciences • Pharmaceuticals
Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.
Market Cap
$1.40B
View Company Details
Pacira BioSciences, Inc. by TradingView
Relevant filing section
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


On March 18, 2023, Yvonne Greenstreet notified the Board of Directors (the "Board") of Pacira BioSciences, Inc. (the "Company") of her intent to of her intent to retire from the Board, effective March 31, 2023. Dr. Greenstreet is currently serving as Chief Executive Officer of Alnylam Pharmaceuticals, Inc., a Nasdaq-listed public company. Pacira is initiating a process to identify an independent Board member to replace Dr. Greenstreet. Dr. Greenstreet's decision to retire was not a result of any disagreement with the Company on any matter relating to the Company's operations, policies, or practices.